Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants.

Hum Vaccin Immunother · 2014 · PMC5443068 · PMID 25483663

Europe PMC DOI

hedged sentence

0.0700

closest p · 1.4× alpha

0.0700

boldest claim

The sentences

a nonsignificant trendP = 0.07so close (0.05 < p ≤ 0.1)

There was a nonsignificant trend of increased PICU stay duration ( P = 0.07) and MV duration ( P = 0.07) as the duration between the most recent palivizumab dose and RSVH increased.

also in 5,406 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.